MeSH D050171 - dyslipidemias
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Inclisiran | Leqvio |  | 2020-12-09 | $284 M | Q2/21-Q2/24 |
| Sanofi | Alirocumab | Praluent |  | 2015-09-23 |  |  |
| Merck & Co | Laropiprant, Nicotinic acid | Pelzont |  | 2008-07-03 |  |  |
| Laropiprant, Nicotinic acid | Tredaptive |  | 2008-07-03 |  |  | |
| Laropiprant, Nicotinic acid | Trevaclyn |  | 2008-07-03 |  |  | |
| Daiichi Pharmaceutical | Bempedoic acid | Nilemdo |  | 2020-04-01 |  |  |
| Bempedoic acid, Ezetimibe | Nustendi |  | 2020-03-27 |  |  | |
| Amarin Corporation | Icosapent ethyl | Vazkepa |  | 2021-03-26 |  |  |
| Amgen | Evolocumab | Repatha |  | 2015-07-17 | $2,033 M | Q4/23-Q3/24 |
| Laboratoires SMB | Fenofibrate, Pravastatin | Pravafenix |  | 2011-04-14 |  |  |
| Viatris | Fenofibrate, Simvastatin | Cholib |  | 2013-08-26 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
72%21/29
Phase 2
65%20/31
Phase 3
59%37/63
Approved: 10Overall Success rate: 27%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use